A study evaluating circulating tumor cell (CTC)-based gene expression for predicting resistance to Abiraterone and Enzalutamide in Patients with metastatic castration resistant prostate cancer (mCRPC)
Latest Information Update: 07 Jun 2017
At a glance
- Drugs Abiraterone (Primary) ; Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 07 Jun 2017 New trial record
- 16 May 2017 Results presented at the 112th Annual Meeting of the American Urological Association